Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 19/20 | 0.54 |
| ▸ | MET | P08581 | 8/20 | 0.54 |
| ▸ | MST1R | Q04912 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | LCK | P06239 | 1/20 | 0.37 |
| ▸ | TEK | Q02763 | 1/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.37 |
| ▸ | FLT1 | P17948 | 7/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1251064 | 1.00 | KDR (0.54) | KDRMETMST1RAURKALCK | |
| SCHEMBL5240822 | 0.91 | MET (0.53) | KDRMETMST1RFLT1 | |
| SCHEMBL5240980 | 0.91 | MET (0.53) | KDRMETMST1RFLT1 | |
| SCHEMBL5243242 | 0.90 | MET (0.52) | KDRMETMST1RAURKALCK | |
| SCHEMBL14409955 | 0.90 | KDR (0.52) | KDRMETMST1RAURKALCK | |
| SCHEMBL5325754 | 0.89 | MET (0.51) | KDRMETMST1RFLT1 | |
| SCHEMBL5241680 | 0.86 | MET (0.54) | KDRMETMST1RAURKALCK | |
| SCHEMBL5243429 | 0.86 | KDR (0.71) | KDRMETMST1RAURKALCK | |
| SCHEMBL5241726 | 0.86 | KDR (0.54) | KDRMETAURKALCKTEK | |
| SCHEMBL5240684 | 0.85 | MET (0.55) | KDRMETMST1RAURKALCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260091079-A1 | SAPOSIN-A DERIVED PEPTIDES AND USES THEREOF | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4685488-A1 | METHOD FOR RENAL CANCER DETECTION | IMBA-Institut für Molekulare Biotechnologie GmbH (AT) | 2026-01-28 | — | — | EP | disclosed |
| US-20250346906-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF CD274/PD-L1 GENE | ALNYLAM PHARMACEUTICALS INC (US) | 2025-11-13 | — | — | US | disclosed |
| US-12285459-B2 | Saposin-A derived peptides and uses thereof | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-04-29 | — | — | US | disclosed |
| CN-114945378-B | Feeder-based and feeder-free stem cell culture systems for stratified epithelial stem cells and related uses thereof | 休斯敦大学体系 | 2024-11-19 | — | — | CN | disclosed |
| US-12117448-B2 | Saposin-A derived peptides and uses thereof | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2024-10-15 | — | — | US | disclosed |
| US-20240316005-A1 | GENE SIGNATURES FOR PREDICTING SURVIVAL TIME IN PATIENTS SUFFERING FROM RENAL CELL CARCINOMA | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2024-09-26 | — | — | US | disclosed |
| EP-4385568-A2 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF CD274/PD-L1 GENE | Alnylam Pharmaceuticals, Inc. (US) | 2024-06-19 | — | — | EP | disclosed |
| EP-4367269-A1 | GENE SIGNATURES FOR PREDICTING SURVIVAL TIME IN PATIENTS SUFFERING FROM RENAL CELL CARCINOMA | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2024-05-15 | — | — | EP | disclosed |
| EP-3578657-B1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF CD274/PD-L1 GENE | ALNYLAM PHARMACEUTICALS INC (US) | 2024-03-20 | — | — | EP | disclosed |
| EP-4306123-A2 | SAPOSIN-A DERIVED PEPTIDES AND USES THEREOF | Children's Medical Center Corporation (US) | 2024-01-17 | — | — | EP | disclosed |
| US-20230285501-A1 | SAPOSIN-A DERIVED PEPTIDES AND USES THEREOF | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2023-09-14 | — | — | US | disclosed |
| US-11590196-B2 | Saposin-A derived peptides and uses thereof | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2023-02-28 | — | — | US | disclosed |
| WO-2023280790-A1 | GENE SIGNATURES FOR PREDICTING SURVIVAL TIME IN PATIENTS SUFFERING FROM RENAL CELL CARCINOMA | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2023-01-12 | — | — | WO | disclosed |
| US-11433068-B2 | Treatment of cancers having alterations within the SWI/SNF chromatin remodeling complex | THE GENERAL HOSPITAL CORPORATION (US) | 2022-09-06 | — | — | US | disclosed |
| CN-114945378-A | Feeder-layer and feeder-layer-free stem cell culture systems for stratified epithelial stem cells and uses related thereto | 休斯敦大学体系 | 2022-08-26 | — | — | CN | disclosed |
| EP-4041259-A1 | FEEDER-BASED AND FEEDER-FREE STEM CELL CULTURE SYSTEMS FOR STRATIFIED EPITHELIAL STEM CELLS, AND USES RELATED THERETO | University of Houston System (US) | 2022-08-17 | — | — | EP | disclosed |
| US-11406709-B2 | Therapeutic and research application of PDCL3 | TRUSTEES OF BOSTON UNIVERSITY (US) | 2022-08-09 | — | — | US | disclosed |
| US-20220137054-A1 | NEW BIOMARKERS AND BIOTARGETS IN RENAL CELL CARCINOMA | UNIVERSITY OF LIVERPOOL (GB) | 2022-05-05 | — | — | US | disclosed |
| US-11236169-B2 | Anti-DEspR monoclonal antibody targeted therapy and imaging for cancer and stroke | TRUSTEES OF BOSTON UNIVERSITY (US) | 2022-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260091079-A1 | SAPOSIN-A DERIVED PEPTIDES AND USES THEREOF | PSAP, VEGFA, ENPEP | KDR 41/4885MET 157/4885MST1R 82/4885 |
| US-20250346906-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF CD274/PD-L1 GENE | CD274, PDCD1LG2, PDCD4 | KDR 2093/4885MET 3049/4885MST1R 1787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.